Beike Biotechnology

Beike is a Chinese biotechnology company with main offices in Shenzhen – located near to Hong Kong – and Taizhou. Our original development of stem cell therapies and their associated clinical applications began over twenty years ago. To date, over 60 leading PhD-qualified scientists from highly ranked Chinese universities contribute to advancing treatments offered by Beike. In addition to the scientists recruited from China, a significant proportion of our employees at Beike have previously worked at Western universities, including Stanford, the University of Minnesota, and UCLA.

The first patient to be treated with Beike processed cells was in 2001, who had been diagnosed with amyotrophic lateral sclerosis (ALS). From our founding, over 200 patients have participated in studies, with many showing discernable improvements in functioning following treatment. Beike was incorporated in July 2005 and has since provided partner hospitals with stem cells for the treatment of over 20,000 patients. Beike currently maintains 25 laboratories for both research and cell processing for clinical use and has received over US$6 million in funding from the government. During 2010, we were privileged to welcome the Chinese Premier Wen Jiabao for a tour of our facilities in Shenzhen.

Unlike many other stem cell treatment clinics, Beike prides itself on developing itself as a research organization. Our passion for helping patients extends beyond using stem cells for treatment based on research from other institutions. In addition to cell therapy, Beike has developed cell technologies and acts as a world leader in this important field. Development in this field has allowed Beike’s treatment protocols and stem cell processing to not only be guided by third-party research, but also aided in the internal development of our own cell therapies. Beike has almost 50 published peer-reviewed research papers in scientific journals around the world, such as Nature, and has spent in excess of ten million dollars over the past decade on cell therapy and research.

Since 2005, Beike has provided partner hospitals in China with stem cells for the treatment of over 20,500 patients. Beike currently provides more than 30 hospitals with umbilical cord, cord blood, and bone marrow-derived stem cells for the treatment of a variety of neurological and vascular conditions. As the sole developer and provider of stem cells to such hospitals, Beike is able to maintain full oversight over cell manufacturing, from the testing of blood products, to cell processing at our laboratories, to delivery of the cells for clinical use. This oversight and integrate process ensures exceedingly high safety and quality levels for patients. In addition, Beike also works closely with partner hospitals in modifying and advancing treatment protocols and patient care. Each partner hospital is equipped with on-hand Beike staff to assist patients both with treatment and general care during their hospital stay.